Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
The same trial that sent Summit up 272% sees the stock crash 36%.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
